# Nuclide record tare-vs-sorafenib-caution (pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pairings/tare-vs-sorafenib-caution/>
  a schema:MedicalTherapy ;
  nuclide:kind "pairing" ;
  schema:identifier "tare-vs-sorafenib-caution" ;
  schema:name "Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma"@en ;
  schema:description "Two large trials tested whether liver-directed radiation beads work better than the pill sorafenib for advanced liver cancer. Neither trial found the radiation beads extended life more than the pill, though patients had fewer side effects and better quality of life with the beads."@en ;
  schema:url <https://nuclide.cc/pairings/tare-vs-sorafenib-caution/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/29107679/>, <https://pubmed.ncbi.nlm.nih.gov/29498924/>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6295389/> ;
  nuclide:tag "hepatocellular carcinoma", "radioembolisation", "negative trial" ;
  nuclide:related <https://nuclide.cc/indications/hcc-intermediate/>, <https://nuclide.cc/indications/hcc/>, <https://nuclide.cc/trials/sarah-sirvenib/>, <https://nuclide.cc/companies/sirtex/>, <https://nuclide.cc/isotopes/y-90/> ;
  nuclide:pairs <https://nuclide.cc/technologies/radioembolisation-tare/>, <https://nuclide.cc/drugs/sorafenib/> .